Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
NCI Cancer Center News

Ibrutinib and rituximab trigger 95 percent response rate among CLL patients

  • Posted: December 13, 2013

Nearly all of the high-risk chronic lymphocytic leukemia patients in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib and the antibody rituximab, researchers from The University of Texas MD Anderson Cancer Center reported at the 55th Annual Meeting of the American Society of Hematology.

Click here to read full press release.


NCI comprehensive cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.